Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes.
Acute and chronic alcohol abuse impairs various functions of the immune system and thus, has been implicated as a cofactor in the immunopathogenesis of human immunodeficiency virus (HIV) disease progression. We determined whether naltrexone, an opioid receptor antagonist widely used in the treatment of alcoholism, inhibits alcohol-mediated enhancement of HIV infection of T cells. Alcohol enhanced HIV infection of peripheral blood lymphocytes (PBL) and a human lymphoid cell line (CEMX174). Alcohol increased HIV X4 envelope (Env), not murine leukemia virus Env-pseudotyped infection of CEMX174 cells. Naltrexone antagonized the enhancing effect of alcohol on HIV infection of PBL and CEMX174 cells. The specific mu-opioid receptor antagonist, Cys2, Tyr3, Arg5, Pen7 (CTAP) amide, also blocked the enhancing effect of alcohol on HIV infection. Investigation of the underlying mechanism for the alcohol action showed that alcohol significantly increased endogenous beta-endorphin production and induced mu-opioid receptor mRNA expression in PBL and CEMX174 cells. The role of beta-endorphin in alcohol-mediated enhancement of HIV infection was indicated by the observations that naltrexone and CTAP antagonized ether alcohol- or exogenous beta-endorphin-mediated enhancement of HIV infection. These findings suggest a biological mechanism for the potential therapeutic benefit of naltrexone in treating HIV-infected alcoholics.
Division of Allergy and Immunology, Joseph Stokes Jr. Research Institute at the Children's Hospital of Philadelphia, 34th Street & Civic Center Boulevard, Philadelphia, PA 19104, USA.
Xu
X
Wang
Steven D
SD
Douglas
Jin-Song
JS
Peng
David S
DS
Metzger
Charles P
CP
O'Brien
Ting
T
Zhang
Wen-Zhe
WZ
Ho
D000328:Adult; D000427:Alcohol Deterrents / Q000494:pharmacology* / Q000627:therapeutic use; D000437:Alcoholism / Q000150:complications / Q000276:immunology; D002478:Cells, Cultured / Q000187:drug effects / Q000821:virology; D004198:Disease Susceptibility; D004353:Drug Evaluation, Preclinical; D000431:Ethanol / Q000494:pharmacology*; D005260:Female; D015658:HIV Infections / Q000209:etiology; D054303:HIV Reverse Transcriptase / Q000032:analysis; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D006822:Hybrid Cells / Q000187:drug effects / Q000821:virology; D009052:Leukemia Virus, Murine / Q000502:physiology; D008214:Lymphocytes / Q000187:drug effects* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000494:pharmacology* / Q000627:therapeutic use; D010446:Peptide Fragments; D010455:Peptides / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D013004:Somatostatin; D013601:T-Lymphocytes / Q000187:drug effects* / Q000821:virology; D015854:Up-Regulation / Q000187:drug effects; D014771:Virion / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects; D001615:beta-Endorphin / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*
D000427:Alcohol Deterrents; C529311:CTAP octapeptide; D010446:Peptide Fragments; D010455:Peptides; D012333:RNA, Messenger; D017450:Receptors, Opioid, mu; D000431:Ethanol; D013004:Somatostatin; D009271:Naltrexone; D001615:beta-Endorphin; D054303:HIV Reverse Transcriptase